• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Verve Therapeutics to Participate in Upcoming Investor Conferences

    5/28/25 7:00:00 AM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VERV alert in real time by email

    BOSTON , May 28, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that management will participate in fireside chats during the following investor conferences:

    • Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 9:20 a.m. ET in New York, NY
    • Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025, at 11:20 a.m. ET in Miami, FL

    Live webcasts will be available in the investor section of the company's website at www.vervetx.com. The webcasts will be archived for 30 days following the fireside chats.

    About Verve Therapeutics 

    Verve Therapeutics, Inc. (NASDAQ:VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The company's lead programs –VERVE-102, VERVE-201, and VERVE-301 – target the three cholesterol drivers of atherosclerosis: low-density lipoprotein cholesterol (LDL-C), triglycerides (TRLs), and lipoprotein (a) [Lp(a)]. VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia (HoFH). VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels. Lp(a) is a genetically validated, independent risk factor for ASCVD, ischemic stroke, thrombosis, and aortic stenosis. For more information, please visit www.VerveTx.com.

    Investor Contact

    Jen Robinson

    Verve Therapeutics, Inc.

    [email protected]

    Media Contact

    Ashlea Kosikowski

    1AB

    [email protected]



    Primary Logo

    Get the next $VERV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VERV

    DatePrice TargetRatingAnalyst
    4/15/2025Neutral → Overweight
    Cantor Fitzgerald
    4/8/2024$15.00Buy
    H.C. Wainwright
    4/13/2023$29.00Buy
    Canaccord Genuity
    2/1/2023$21.00Neutral
    Cantor Fitzgerald
    12/15/2022$13.00Sell
    Goldman
    10/6/2022$48.00Neutral
    Credit Suisse
    8/25/2022$32.00 → $56.00Hold → Buy
    Stifel
    6/17/2022$48.00Outperform
    BMO Capital Markets
    More analyst ratings

    $VERV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Coats Lonnel

      4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

      6/6/25 5:01:02 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Cumbo Alexander

      4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

      6/6/25 5:01:06 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Morrison Jodie Pope

      4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

      6/6/25 5:00:55 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    SEC Filings

    See more
    • SEC Form SC14D9C filed by Verve Therapeutics Inc.

      SC14D9C - Verve Therapeutics, Inc. (0001840574) (Subject)

      6/17/25 4:21:23 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC TO-C filed by Verve Therapeutics Inc.

      SC TO-C - Verve Therapeutics, Inc. (0001840574) (Subject)

      6/17/25 4:04:51 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Verve Therapeutics Inc.

      8-K - Verve Therapeutics, Inc. (0001840574) (Filer)

      6/17/25 7:18:43 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    Leadership Updates

    Live Leadership Updates

    See more
    • Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

      WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

      4/1/25 7:00:00 AM ET
      $ABOS
      $CLYM
      $LENZ
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer

      BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Frederick "Fred" T. Fiedorek, M.D., as chief medical officer (CMO). Andrew Bellinger, M.D., Ph.D., the current chief scientific officer (CSO) and CMO, will transition to the role of CSO. "We are excited by the continued expansion of the Verve team and the execution of a plan to become a multi-product clinical-stage company," said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve. "Our heart-1 clinical trial is well underway, wi

      9/18/23 6:30:00 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verve Therapeutics Appoints Experienced Biotechnology Executive, Alexander G. "Bo" Cumbo, to its Board of Directors

      CAMBRIDGE, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Alexander G. "Bo" Cumbo, chief executive officer and president of AavantiBio, Inc., has joined the company's board of directors. "Bo is a highly experienced industry executive with a well-established track record of leading pharmaceutical and life sciences companies through critical processes in drug development and commercial execution," said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve. "As we focus on continued execution of our regulatory

      6/13/22 6:30:00 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

      Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease Lilly's established capabilities in cardiometabolic disease and genetic medicines are highly complementary to Verve's vision and expertise INDIANAPOLIS, June 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ:VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, today announced a definitive agreement for Lilly to acquire Verve. Verve is developing a pipeline of gene editing medicines designed to address the drivers of atherosclerotic cardiovasc

      6/17/25 6:45:00 AM ET
      $LLY
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on May 30, 2025, the company granted equity awards to four new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options to purchase an aggregate of 65,000 shares of the company's common stock and an aggregate of 22,000 restricted stock units (RSUs). The options have an exercise price of $4.45 per share, which is equal to

      6/2/25 4:05:00 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verve Therapeutics to Participate in Upcoming Investor Conferences

      BOSTON , May 28, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that management will participate in fireside chats during the following investor conferences: Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 9:20 a.m. ET in New York, NYGoldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025, at 11:20 a.m. ET in Miami, FL Live webcasts will be available in the investor section of the company's website at www.vervetx.com. The webcasts will be archived for 30 days following the fireside chats. About Verve Therapeutics Verve Therapeutics,

      5/28/25 7:00:00 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care